Results 81 to 90 of about 15,200 (191)

Cytokine Dynamics in Bortezomib‐Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans

Journal of the Peripheral Nervous System, Volume 31, Issue 1, March 2026.
ABSTRACT Background and Aims Bortezomib‐induced peripheral neuropathy (BIPN) remains a common treatment side effect in patients with multiple myeloma (MM). Data from rodent models indicate a role of proinflammatory cytokines in BIPN pathophysiology, making them potential therapeutic targets.
Nadine Cebulla, Daniel Schirmer, Eva Runau, Leon Flamm, Calvin Terhorst, Laura Jähnel, Johanna Güse, Nicola Giordani, Annett Wieser, Felicitas Schoch, Marie‐Luise Reinle, Sonja Gommersbach, Aikaterini Papagianni, Xiang Zhou, Hermann Einsele, Ann‐Kristin Reinhold, Heike Rittner, K. Martin Kortüm, Claudia Sommer   +18 more
wiley   +1 more source

Resultados en salud en el tratamiento del mieloma múltiple [PDF]

, 2019
Introducción: El mieloma múltiple es una neoplasia caracterizada por la proliferación incontrolada de células plasmáticas. Es necesario realizar un análisis retrospectivo para evaluar la efectividad de los tratamientos administrados ...
Aguado Paredes, Alicia
core  

Therapy‐Related Acute Myeloid Leukemia Following Plasma Cell Leukemia: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT With the improvement of survival in multiple myeloma (MM), therapy‐related acute myeloid leukemia (t‐AML) has emerged as a clinically relevant second primary malignancy (SPM). We report a case of MM evolving into t‐AML after multi‐agent chemotherapy and review the literature on therapy‐related leukemias in MM.
Songdi Chen, Junqing Hu, Qian Zhang, Luling Mao, Qian Jiang, Chuyun Qian, Weize Zhang, Keting Jin, Jianhu Li, Ji‐nuo Wang, Yi Zhao   +10 more
wiley   +1 more source

Immune and Pathologic Responses in Patients With Localized Prostate Cancer Who Received Daratumumab (Anti-CD38) or Edicotinib (Csf-1R Inhibitor) [PDF]

, 2023
BACKGROUND: The prostate tumor microenvironment (TME) is immunosuppressive, with few effector T cells and enrichment of inhibitory immune populations, leading to limited responses to treatments such as immune checkpoint therapies (ICTs).
Basu, Sreyashi, Chapin, Brian F, Corn, Paul G, Drake, Charles G, Duan, Fei, Espejo, Alexsandra B, Gottardis, Marco, Gu, Ai-Di, Hutnick, Natalie, Jindal, Sonali, Kinder, Michelle, Knoblauch, Roland, Logothetis, Christopher J, Pettaway, Curtis A, Sharma, Padmanee, Siddiqui, Bilal A, Subudhi, Sumit K, Tidwell, Rebecca S S, Troncoso, Patricia, Ward, John F, Yadav, Shalini S   +20 more
core   +1 more source

Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma

Journal of Extracellular Vesicles, Volume 15, Issue 2, February 2026.
Multiple myeloma peripheral blood extracellular vesicles (EVs) are a source of non‐invasive biomarkers with potential for routine monitoring and to complement or replace invasive bone marrow biopsy. In this study, five proteins were significantly different from healthy controls and three associated with long‐term response on Daratumumab which may have ...
Kieran Brennan, Katrine F. Iversen, Alfonso Blanco‐Fernández, Thomas Lund, Torben Plesner, Margaret M. Mc Gee   +5 more
wiley   +1 more source

Hemophagocytic Lymphohistiocytosis as First Manifestation of Dual B‐Cell Neoplasms: A Case Report of Co‐Existing Multiple Myeloma and B‐Cell Lymphoma

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Hemophagocytic lymphohistiocytosis (HLH) is an immune disorder causing excessive inflammation and tissue damage. Lymphoma, especially T‐cell lymphoma, is the most common cause of HLH, while Multiple Myeloma (MM) is rarely associated. We present a 61‐year‐old man with spiking fevers, fatigue, and unintentional weight loss. The HLH was driven by
Carla Romagnoli, Alexandra Lyubimova, Leily Santos‐Carrion, Ferial Alloush, Vathany Sriganeshan, Andrea Noboa, Jacqueline C. Barrientos   +6 more
wiley   +1 more source

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

Haematologica, 2015
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated ...
Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale Andre, Yannis Morel, Henk M. Lokhorst, Niels W.C.J. van de Donk, Paul W.H.I. Parren, Tuna Mutis   +8 more
doaj   +1 more source

Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT This study demonstrates the application of a model based meta analysis (MBMA) framework to characterize the safety and efficacy profiles of therapies in relapsed and refractory multiple myeloma (RRMM). Published clinical trial data were analyzed to evaluate the incidence of Grade ≥ 3 neutropenia and overall response rate (ORR), providing a ...
Zeel Shah, Clifton M. Anderson, Kevin D. McCormick, Celeste Vallejo, William Duncan, Chuanpu Hu, Jian Zhou, Alexander V. Ratushny, Anna G. Kondic   +8 more
wiley   +1 more source

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management

Journal of Internal Medicine, Volume 299, Issue 2, Page 196-215, February 2026.
Abstract Cryoglobulinemia (CG) is defined by the presence of serum immunoglobulins that precipitate below 37°C and redissolve upon rewarming. It is classified into three types based on immunoglobulin composition. Type I, a rare form, involves monoclonal IgM or IgG and is linked to lymphoproliferative disorders.
Anna Linda Zignego, Laura Gragnani, Marcella Visentini, Riccardo Bomben, Luca Arcaini, Clodoveo Ferri, Valter Gattei, Cesare Mazzaro   +7 more
wiley   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

International Journal of Cancer, Volume 158, Issue 2, Page 423-432, 15 January 2026.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar, Lev M. Kats, Emily Gruber   +2 more
wiley   +1 more source